DoH Policies screened during the period - 1 April 2025 – 30 June 2025
Date published:
In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact.
Documents
- Temporary suspension of non-therapeutic paediatric male circumcision waiting lists (PDF 358KB)
- Keeping Children and Young People Safe - An Online Safety Strategy (PDF 420KB)
- NICE Clinical Guideline NG246 - Overweight and obesity management (PDF 376KB)
- NICE Technology Appraisal TA1046 - Zolbetuximab with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma (PDF 300KB)
- NICE Technology Appraisal TA1048 - Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitable (PDF 303KB)
- NICE Technology Appraisal TA1049 - Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia (PDF 299KB)
- NICE Technology Appraisal TA1050 - Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over (PDF 302KB)
- NICE Technology Appraisal TA1051 - Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over (PDF 302KB)
- NICE Technology Appraisal TA1053 - Cladribine for treating active relapsing forms of multiple sclerosis (PDF 299KB)
- NICE Technology Appraisal TA1054 - Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over (review of TA839) (PDF 300KB)
- NICE Technology Appraisal TA1055 - Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first[1]line platinum-based chemotherapy (PDF 322KB)
- NICE Technology Appraisal TA1056 - Molnupiravir for treating COVID-19 (PDF 301KB)
- NICE Technology Appraisal TA1057 - Relugolix–estradiol–norethisterone for treating symptoms of endometriosis (PDF 300KB)
- NICE Technology Appraisal TA1059 - Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma (review of TA594) (PDF 299KB)
- NICE Technology Appraisal TA1060 - Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer (PDF 299KB)
- NICE Technology Appraisal TA1062 - Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor (PDF 298KB)
- NICE Technology Appraisal TA1063 - Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment (PDF 299KB)
- NICE Technology Appraisal TA1064 - Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (review of TA963) (PDF 300KB)
- NICE Technology Appraisal TA1065 - Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (PDF 298KB)
- NICE Technology Appraisal TA1066 - Somapacitan for treating growth hormone deficiency in people 3 to 17 years (PDF 298KB)
- NICE Technology Appraisal TA1067 - Linzagolix for treating symptoms of endometriosis (PDF 300KB)
- NICE Technology Appraisal TA1069 - Efgartigimod for treating antibody-positive generalised myasthenia gravis (PDF 298KB)
- NICE Technology Appraisal TA1070 - Spesolimab for treating generalised pustular psoriasis flares (PDF 322KB)